Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can doctor training boost lung cancer care in smaller cities?

NCT ID NCT06494241

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether educating doctors in small and mid-sized city hospitals can improve how they test and treat patients with advanced non-small cell lung cancer. About 1000 patients will be observed to see if more patients get the right molecular tests and targeted treatments after the education program. The goal is to improve care in areas that may not have access to the latest guidelines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,000 people

The number who actually took part.

Started

Nov 2024

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC will be enrolled. Approximately 1000 patients will be enrolled from about 50 sites in China.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years, at the time of signing the informed consent. * ECOG performance status 0-2. * Newly pathologic diagnosed metastatic NSCLC (clinical stage IV) or recurrent metastatic NSCLC. Exclusion Criteria: * Be participating in other intervention clinical trials. * Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. * Previous enrolment in the other QIP study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bronchial neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchial neoplasm bronchogenic carcinoma lung disorder lung neoplasm neoplasm neoplasm of thorax Neoplasms by Site non-small cell lung carcinoma respiratory system disorder respiratory tract neoplasm Thoracic Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bronchial neoplasms Carcinoma, bronchogenic Carcinoma, non-small-cell lung Lung diseases Lung neoplasms Neoplasms Neoplasms by site Respiratory tract diseases Respiratory tract neoplasms Thoracic neoplasms

Contacts and locations

Locations

  • Research Site

    Anning, China

  • Research Site

    Anqing, China

  • Research Site

    Changzhi, China

  • Research Site

    Daqing, China

  • Research Site

    Dazhou, China

  • Research Site

    Dazhu, China

  • Research Site

    Dingzhou, China

  • Research Site

    Ganzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guang’an, China

  • Research Site

    Hanzhong, China

  • Research Site

    Hebi, China

  • Research Site

    Hengyang, China

  • Research Site

    Huaibei, China

  • Research Site

    Jining, China

  • Research Site

    Jinzhou, China

  • Research Site

    Liyang, China

  • Research Site

    Lu'an, China

  • Research Site

    Meihekou, China

  • Research Site

    Nanchong, China

  • Research Site

    Nanyang, China

  • Research Site

    Ningde, China

  • Research Site

    Ningxiang, China

  • Research Site

    Panjin, China

  • Research Site

    Pingxiang, China

  • Research Site

    Quanzhou, China

  • Research Site

    Shengzhou, China

  • Research Site

    Suzhou, China

  • Research Site

    Taizhou, China

  • Research Site

    Tancheng, China

  • Research Site

    Tongling, China

  • Research Site

    Wafangdian, China

  • Research Site

    Weifang, China

  • Research Site

    Wuzhou, China

  • Research Site

    Xiangtan, China

  • Research Site

    Xianning, China

  • Research Site

    Xiantao, China

  • Research Site

    Xixian, China

  • Research Site

    Xuzhou, China

  • Research Site

    Yangjiang, China

  • Research Site

    Yangzhou, China

  • Research Site

    Yibin, China

  • Research Site

    Yichun, China

  • Research Site

    Yingkou, China

  • Research Site

    Zhangjiakou, China

  • Research Site

    Zhuji, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.